Linagliptin as add ‐on to empagliflozin in a fixed‐dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two‐part, randomized, placebo‐controlled trial

Diabetes, Obesity and Metabolism,Volume 0, Issue ja, -Not available-.

Source: Diabetes, Obesity and Metabolism - August 9, 2018 Category: Endocrinology Authors: Kohei Kaku MD PhD , Masakazu Haneda MD PhD , Yuko Tanaka BPharm , Ganghyuck Lee MSc , Kosuke Shiki MSc , Yuki Miyamoto MD , Fernando Solimando MD , Jisoo Lee MD , Christopher Lee MBBS PhD , Jyothis George MD PhD Source Type: research